Vivelle-Dot treats moderate to severe hot flashes, night sweats and vaginal atrophy and dryness associated with menopause and is offered in a range of dosage strengths. It is an estrogen-only treatment. Patients who have vasomotor symptoms associated with menopause but still have a uterus, can consider CombiPatch® (estradiol/norethindrone acetate transdermal system) treatment or should take progestin with Vivelle-Dot to protect against uterine cancer.
Vivelle-Dot is the smallest estrogen therapy (ET) patch available.
Vivelle-Dot Features Include:
- Proven relief of moderate to severe hot flashes, night sweats and vaginal atrophy and dryness associated with menopause
- Prevention of postmenopausal osteoporosis
- Smaller total doses than pills. Transdermals achieve therapeutic levels with smaller doses compared to oral therapy. This does not imply differences in safety or efficacy
- The smallest, barely visible estrogen patch available
- Twice-a-week dosing
- For women interested in the source of estrogen in their therapy, the estrogen in Vivelle-Dot (estradiol) is chemically synthesized from a plant source. This does not mean that Vivelle-Dot is safer or more effective than other hormone therapies
Small Size and Wearability
Vivelle-Dot is the smallest estrogen therapy patch available today for treatment of moderate to severe hot flashes, night sweats and vaginal atrophy and dryness associated with menopause. The 0.05 mg/day patch is about the size of a standard postage stamp.
Vivelle-Dot stays on during exercise, in the shower, and even in the swimming pool.
Why Choose Larger Total Doses Than Your Patients Need? When Smaller Will Do
The skin metabolizes estradiol only to a small extent. In contrast, orally administered estradiol is rapidly metabolized by the liver to estrone and its conjugates, giving rise to higher circulating levels of estrone than estradiol. Therefore, transdermal administration produces therapeutic levels of estradiol with lower circulating levels of estrone and estrone conjugates and requires smaller total doses than oral therapy. This does not imply increased safety or efficacy.
Advanced System for Estrogen Delivery
Vivelle-Dot was developed using the patented DOT Matrix® delivery technology. "DOT" stands for "Delivery Optimized Thermodynamics." DOT Matrix technology works by using a drug/acrylic blend mixed with silicone adhesive that forms evenly-dispersed, concentrated drug pockets. The concentration gradient between the adhesive system and the skin allows for highly efficient diffusion. In addition, DOT Matrix technology allows Vivelle-Dot to be the smallest estrogen therapy patch available, and helps the Vivelle-Dot patch stay on continuously with a low occurrence of irritation.
Due to DOT Matrix, Vivelle-Dot is capable of maintaining predictable and effective estrogen delivery for the relief of moderate to severe vasomotor symptoms associated with menopause symptoms and the prevention of postmenopausal osteoporosis. Vivelle-Dot provides estradiol, which is the primary form of estrogen produced by the ovaries.
Benefits of Vivelle-Dot
Women need only apply the Vivelle-Dot patch twice a week for proper dosing and to help control their moderate to severe vasomotor symptoms associated with menopause and to prevent postmenopausal osteoporosis.
Vivelle-Dot is a tiny, thin, translucent patch. Women apply the discreet patch on the skin of the lower abdomen.
For women who are interested in the source of the estrogen in their therapy, the estrogen in Vivelle-Dot (estradiol) is chemically synthesized from a plant source. This does not mean that Vivelle-Dot is safer or more effective than other hormone therapies.
Most Common Side Effects
In clinical trials with Vivelle, the most common side effects were headache, breast tenderness, and back pain.